Efficient Gene Therapy Manufacturing for Ocular Diseases

Time: 4:35 pm
day: Day One


  • Targeting sensitive biological spaces, such as the eye, require highly purified and well characterized products
  • AAV therapeutics for ophthalmic dosing require low endotoxin, residuals, and empty particle contaminant levels
  • Scalable processes that maintain high productivity and purity of the vector